➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Moodys
Dow
Mallinckrodt
Colorcon

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,877,933

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,877,933 protect, and when does it expire?

Patent 8,877,933 protects NEXAVAR and is included in one NDA.

This patent has forty-two patent family members in thirty-one countries.

Summary for Patent: 8,877,933
Title:Thermodynamically stable form of a tosylate salt
Abstract: The present invention relates to a novel form, thermodynamically stable at room temperature, of the tosylate salt of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}- -N-methylpyridine-2-carboxamide, to processes for its preparation, to medicaments comprising it and to its use in the control of disorders.
Inventor(s): Grunenberg; Alfons (Dormagen, DE), Lenz; Jana (Wuppertal, DE)
Assignee: Bayer Intellectual Property GmbH (Monheim, DE)
Application Number:11/664,363
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,877,933
Patent Claim Types:
see list of patent claims
Compound; Use; Composition; Process;

Drugs Protected by US Patent 8,877,933

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bayer Hlthcare NEXAVAR sorafenib tosylate TABLET;ORAL 021923-001 Dec 20, 2005 RX Yes Yes   Start Trial   Start Trial Y Y TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA, ADVANCED RENAL CELL CARCINOMA, OR DIFFERENTIATED THYROID CARCINOMA.   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,877,933

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
04023130Sep 29, 2004
PCT Information
PCT FiledSeptember 20, 2005PCT Application Number:PCT/EP2005/010119
PCT Publication Date:April 06, 2006PCT Publication Number: WO2006/034797

International Family Members for US Patent 8,877,933

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 051301   Start Trial
Australia 2005289100   Start Trial
Brazil PI0515946   Start Trial
Canada 2581843   Start Trial
China 101065360   Start Trial
Cuba 20070068   Start Trial
Cyprus 1113598   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Johnson and Johnson
Moodys
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.